What is the efficacy of Rosuvastatin for preventing cardiovascular events in people with elevated C-reactive protein?
The efficacy of Rosuvastatin for preventing vascular events in people with elevated C-reactive protein has been demonstrated in several clinical trials, such as the N Engl J Med study in 2008, the Cochrane Database System Review in 2013, the N Engl J Med study in 2016, the JAMA study in 2016, the Lancet study in 2004, the Lancet study in 2003, the Drugs study in 2012, the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) in 2006, the General Practice Research Database study in 2008, and the Diabetologia study in 2008. These studies have demonstrated that Rosuvastatin is effective in reducing the risk of cardiovascular events in both men and women with elevated C-reactive protein levels. 